References
- Akcali A, Pehlivan S, Pehlivan M, et al (2010). TNF-alpha promoter polymorphisms in multiple sclerosis: no association with -308 and -238 alleles, but the -857 alleles in associated with the disease in Turkish patients. Int J Immunogenet, 37, 91-5. https://doi.org/10.1111/j.1744-313X.2009.00895.x
- Banu C, Moise A, Arion CV, et al (2011). Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients. J Med Life, 4, 264-8.
- Bivalacqua TJ, Champion HC, Hellstrom WJG (2002). Implications of nitric oxide synthases isoforms in the pathophysiology of Peyronie’s disease. Int J Imp Res, 14, 345-2. https://doi.org/10.1038/sj.ijir.3900872
- Black RA, Rauch CT, Kozlosky CJ, et al (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385, 729-33. https://doi.org/10.1038/385729a0
- Buda G, Maggini V, Galimberti S, et al (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 137, 454-6. https://doi.org/10.1111/j.1365-2141.2007.06605.x
- Buda G, Ricci D, Huang CC, et al (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 89, 1133-40. https://doi.org/10.1007/s00277-010-0992-3
- Cox DR (1972). Regression models and life-tables. J R Stat Soc Ser B, 34, 187-220.
-
Dogra S, Khullar G (2013). Tumor necrosis factor-
${\alpha}$ antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 7, 35-46. - Drain S, Catherwood MA, Orr N, et al (2009). ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma, 50, 566-570. https://doi.org/10.1080/10428190902853144
- Du J, Yuan ZG, Zhang CY, et al (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi, 30, 649-53.
- Game X, Rischmann P, Arnal JF, et al (2013). Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role]. Prog Urol, 23, 926-35. https://doi.org/10.1016/j.purol.2013.07.005
- Germann, UA (1996). P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 32, 927-44. https://doi.org/10.1016/0959-8049(96)00057-3
- Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vasculer invasion in human breast cancer is coralated to T->786C polymophism of NOS3 gene. Nitric Oxide, 9, 118-22. https://doi.org/10.1016/j.niox.2003.09.002
- Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-55. https://doi.org/10.1007/s10549-005-9143-2
- Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86,134-37. https://doi.org/10.1006/gyno.2002.6749
- Heil M, Eitenmuller I, Schmitz-Rixen T, et al (2006). Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med, 10, 45-55. https://doi.org/10.1111/j.1582-4934.2006.tb00290.x
- Ichimaru M, Ishimaru T, Mikami M, et al (1982). Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow. J Natl Cancer Inst, 69, 323-28.
- Iokupova EV, Grinchuk OV, Kalimullina DKh, et al (2003). Molecular genetic analysis of the IL-6 and Tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk), 37, 420-24.
- Jamroziak K, Balcerczak E, Cebula B, et al (2005). Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep, 57, 882-8.
- Juliano RL, Ling VA (1976). Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62. https://doi.org/10.1016/0005-2736(76)90160-7
- Kadar K, Kovacs M, Karadi I, et al (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 32, 1499-504. https://doi.org/10.1016/j.leukres.2008.03.001
- Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81. https://doi.org/10.1080/01621459.1958.10501452
- Knop S (2014). The multiple myeloma - current view and perspectives. Med Monatsshr Pharm, 37, 84-92.
- Kyle RA (1994). Multiple myeloma: How did it begin? Mayo Clin Proc, 69, 680-83. https://doi.org/10.1016/S0025-6196(12)61349-4
- Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50. https://doi.org/10.1097/00008469-200208000-00005
- Nakamura K, Matsuzawa N, Ohmori S, et al (2013). Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metab Pharmacokinet, 28, 38-43. https://doi.org/10.2133/dmpk.DMPK-12-RV-089
- Nathan C, Xie QW (1994). Nitric oxide synthases. Roles, tolls and controls. Cell, 78, 915-8. https://doi.org/10.1016/0092-8674(94)90266-6
-
Neben K, Mytilineos J, Moehler TM, et al (2002). Polymorphisms of the tumor necrosis factor-
${\alpha}$ gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-65. - Olmos G, Llado J (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm, 2014, 861231.
- Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90. https://doi.org/10.1016/j.ygyno.2004.03.030
- Wajant H, Pfizenmaier K, Scheurich P (2003). Tumor necrosis factor signaling. Cell Death Differ, 10, 45-65. https://doi.org/10.1038/sj.cdd.4401189
- Wang SS, Davis S, Cerhan JR, et al (2006). Polymorphisims in oxidative stres genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27, 1828-34. https://doi.org/10.1093/carcin/bgl013
Cited by
- The Genes of Life and Death: A Potential Role for Placental-Specific Genes in Cancer vol.39, pp.11, 2017, https://doi.org/10.1002/bies.201700091